A new clinical trial is testing whether a non-invasive brain stimulation device can help millions of people with moderate-to-severe insomnia avoid sleep medications altogether. Nexalin Technology announced in April 2026 that its HALO Clarity device is advancing toward enrollment in a pivotal study designed to support an FDA submission. The trial represents a significant step toward bringing a drug-free treatment option to patients who struggle with existing sleep medications or prefer alternatives.

How Does This Brain Stimulation Device Work?

The HALO Clarity uses a technology called Deep Intracranial Frequency Stimulation (DIFS), which delivers targeted electrical stimulation to deep brain structures associated with sleep regulation. Unlike invasive brain surgery, the device is non-invasive and undetectable to the human body, according to Nexalin. The company believes this deeper-penetrating approach can address the root causes of insomnia without the side effects associated with sleep medications.

Nexalin's approach builds on earlier peer-reviewed research showing statistically significant improvements in sleep outcomes compared to sham treatment. The company has also gathered neuroimaging data suggesting the device affects brain regions involved in chronic insomnia and other mental health conditions.

What Will the Clinical Trial Actually Test?

The pivotal trial is designed as a randomized, triple-blinded, sham-controlled study involving 160 participants. Triple-blinded means that patients, researchers, and data analysts won't know who received the active device versus a placebo treatment, which helps eliminate bias. Patient enrollment is expected to begin in the second quarter of 2026.

The trial is being conducted in collaboration with Lindus Health, an Accountable Research Organization (ARO) that specializes in clinical trial execution. Lindus Health will handle everything from protocol finalization through data analysis, including patient recruitment, regulatory submissions, and statistical analysis.

Why Does This Matter for Insomnia Patients?

Insomnia affects millions of people, yet many face significant limitations with current treatment options. Common concerns include medication side effects, dependency risks, and inconsistent long-term outcomes. A non-pharmacologic alternative could address these gaps for patients who don't respond well to or prefer to avoid sleep medications.

The global sleep technology market was valued at approximately $29.3 billion in 2025 and is projected to reach about $153.7 billion by 2035, reflecting growing demand for innovative sleep solutions.

Steps to Understanding This Clinical Trial Development

• De Novo Pathway: If the trial succeeds, Nexalin plans to submit a De Novo Classification Request to the FDA, which would establish the HALO Clarity as an entirely new product category rather than comparing it to existing devices.
• Triple-Blinded Design: This rigorous study design prevents patients, researchers, and analysts from knowing who received the active treatment, reducing bias and strengthening the evidence.
• Peer-Reviewed Foundation: The trial builds on previously published clinical data showing statistically significant improvements, providing a scientific foundation for the larger study.
• Broader Mental Health Applications: Beyond insomnia, Nexalin is investigating the device for depression, traumatic brain injury, post-traumatic stress disorder, Alzheimer's disease, and attention-deficit/hyperactivity disorder.

Mark White, Chief Executive Officer of Nexalin Technology, stated that the company believes the HALO Clarity represents "a unique and advanced approach to non-invasive drug-free treatment for patients with moderate-to-severe insomnia." He added that if the study yields anticipated results and regulatory milestones are achieved, the device "could offer a differentiated, non-pharmacologic alternative for patients and providers".

Mark White, Chief Executive Officer of Nexalin Technology

"Insomnia and mental health challenges affect millions of patients, yet many continue to face limitations with existing treatment options, including tolerability concerns, dependency risk, side effects and inconsistent long-term treatment outcomes," said Mark White, Chief Executive Officer of Nexalin Technology.

Mark White, Chief Executive Officer, Nexalin Technology

What's the Timeline for FDA Approval?

The company expects patient enrollment to begin in the second quarter of 2026, but the full timeline for trial completion and FDA submission remains uncertain. Clinical trials typically take several years from enrollment through data analysis and regulatory review. Nexalin has indicated it will provide updates on site activation and enrollment progress as the trial advances.

The HALO Clarity device has already received approval in China, Brazil, Oman, and Israel, suggesting the technology has demonstrated safety and efficacy in international markets. However, FDA approval in the United States would represent a major milestone and could significantly expand patient access.

Key Takeaways

The HALO Clarity trial represents an important development for insomnia treatment, offering a potential non-medication option for millions of people. The rigorous, triple-blinded design and collaboration with an experienced research organization suggest a serious commitment to generating high-quality evidence. While results won't be available for several years, this trial could eventually provide patients with a new tool for managing one of the most common sleep disorders. Anyone interested in participating in sleep-related clinical trials should discuss options with their healthcare provider or visit ClinicalTrials.gov to search for studies in their area.